# Learning to Think Like a Clinical Development Professional: Eight Months In

*By Andrea Grioni*

---

When I joined Clinical Development as part of the clinical trial team, I expected the biggest challenge to be the workload — the documents to draft, the meetings to run, the country calls to join at odd hours. And yes, all of that is real. But the shift that reshaped how I think happened more quietly. I had to learn to see a clinical trial the way the people who run it do, not the way a data scientist does.

In biomarker development, I was trained to ask: *what does the data say?* In clinical development, the question that precedes everything else is: *how do we make sure we have data worth asking questions of?* That subtle inversion has been the most profound lesson of my first eight months.

---

## The Daily Reality Nobody Puts in the Job Description

Much of my day looks nothing like what I imagined when I was entrusted with this role. Early on, I helped write documents directly — contributing to the clinical development plan, for example — but that turned out to be a small fraction of the actual work. The real shape of my week is alignment. I work closely with data management on how trial data is captured and cleaned, with biostatisticians on the statistical analysis plan and the questions it needs to answer, and with operations and country teams on the day-to-day execution of the protocol — answering questions from sites and local staff about how the protocol should be applied in specific situations, and flagging issues that come up at individual sites so they can be addressed before they spread.

If I had to describe the texture of my days in one phrase, it would be: *sustained alignment across people who see the same trial differently*.

Clinical development is not a solo discipline. A protocol decision that looks straightforward from a scientific standpoint may create operational problems for a country team, for the regulatory team, or feasibility concerns for the sites. My job, much of the time, is to sit at the intersection of those perspectives and help the team arrive at a decision that everyone can execute. Country calls are a good example — connecting with local teams to understand what is actually happening at the sites, where the friction is, what the protocol looks like from the perspective of a coordinator managing ten trials at once. That ground-level view is irreplaceable, and it only comes from asking and listening, not from the data alone.

This is where the transition out of the individual contributor role has been most tangible. As a data scientist, I was accountable for my analyses. As part of a clinical trial team, I am accountable for the conditions under which good work becomes possible — and that is a fundamentally more human, less computational problem.

---

## Outcome Trials vs. "Regular" Trials: A Distinction That Changes Everything

Soon after starting the new role, I attended a presentation that a very experienced clinical development leader gave to country leaders. At one point, almost in passing, he said it plainly: *"Outcome trials are a different animal."* At the time I nodded, assuming I understood. Eight months later, I think I am only beginning to appreciate what he meant.

In typical Phase II or Phase III trials, the primary endpoint is measured at a defined moment. A patient comes in at week 24, you collect a lab value or a symptom score, and that is your data point. The visit schedule is the backbone of the trial. You know roughly when you will have what you need.

An outcome trial works on a completely different logic. The primary endpoint is a clinical event — a heart attack, a hospitalization, death — and the fundamental challenge is that you do not know when, or whether, it will happen for any given patient. You cannot schedule an event. You can only keep the patient in the trial long enough, and monitored closely enough, that if it happens, you capture it. This means the trial has to remain operationally alive and vigilant across years, not just across scheduled visits. Every missed contact, every patient who quietly disengages, is not a gap in a timepoint — it is a window during which an event could occur and go undetected. That possibility is what makes retention not just an operational inconvenience but a scientific and ethical obligation.

This was the shift that most recalibrated my thinking. In biomarker work, a missing visit is a missing data point. In an outcome trial, a missing patient is a missing story — and that story might be the primary endpoint.

---

## Retention and Endpoint Collection: Where Science Meets Care

Retention — keeping patients enrolled and engaged over years — requires an operational and almost relational discipline that has no real equivalent in the world of algorithms. It means designing visit schedules that are realistic for people with chronic illness. It means training site staff to recognize early signs of disengagement. It means understanding why a patient in one country might find it harder to come back for a follow-up than a patient in another, and building that into your planning.

Endpoint collection is equally unforgiving. In an outcome trial, whether a cardiac event is adjudicated as the primary endpoint or not depends on documentation that was collected at a specific moment, in a specific format, by a specific person at the site. A data scientist's reflex is to trust the data pipeline. A clinical developer's reflex is to audit the human chain that feeds it. I am still building that second reflex.

In biomarker work, missing data is an analytical challenge — you impute, you run sensitivity analyses, you document. In an outcome trial, missing data is a trial-integrity challenge. The difference is not merely academic.

---

## What My Data Science Background Gets Right — and Gets Wrong

I want to be honest about both sides of this, because I think the "your skills transfer!" narrative, while true in part, can obscure the real adjustment required.

What transfers well: the ability to read a statistical analysis plan critically, to spot an endpoint definition that will create ambiguity at adjudication, and a sharper eye for data and numbers when reviewing protocol feasibility and study metrics. The ability to look at data with different tools and mindsets, moving from a single patient profile to gather signals and patterns generated by the analysis of the entire trial. In meetings, this has occasionally shifted the direction of a conversation.

What transfers poorly: the assumption that complexity can be managed by better tooling or better analysis. That no single solution fits all — the same trial takes on multiple shapes and colors when you drill down to the country level, where each region brings its own regulations and laws that you need to account for. In clinical development, many of the hard problems are human and regulatory — they require negotiation, precedent, and patience rather than a smarter model. I have had to learn to sit with uncertainty for longer than I am comfortable with, and to trust processes that move at institutional speed rather than computational speed.

---

## Where AI and Advanced Analytics Genuinely Move the Needle

That said, the more I see clinical development from the inside, the more convinced I am that AI — generative AI in particular — and advanced analytics have a real and still underused role to play here. Not as a replacement for clinical judgment or operational expertise, but as a force multiplier for both.

The most immediate contribution is in simplifying and accelerating work that has historically been slow and labor-intensive. Data review is a clear example. The volume of information generated by an outcome trial — across thousands of patients, hundreds of sites, years of follow-up — is beyond what any single team can examine line by line. Large language models, for instance, can take unstructured medical notes submitted by sites, parse the clinical narrative, and reshape it into a structured format that a downstream pipeline can then compare against the rest of the subject's clinical record — flagging missing information, inconsistencies, or events that were observed but never formally reported. That kind of extraction and cross-referencing, done manually, would take hours per patient and scale poorly. Done programmatically, it becomes a systematic quality layer that runs in the background of the trial. The same principle applies to medical writing, regulatory documentation, and the synthesis of meeting outcomes.

Generative AI is also doing something less obvious but equally important: it is democratizing the ability to write, develop, and validate code. In a field where most professionals are not trained programmers, the ability to generate, test, and document code chunks for clinical data review — without needing a dedicated software engineer for every task — changes who can build automation and how quickly. A clinical development professional who can describe a review logic in plain language and turn it into a validated script represents a real shift in operational capacity.

The broader contribution of a data science mindset is in how it frames the detection of problems. Clinical trial teams have always looked for issues in their data — but historically, this has relied heavily on manual review and expert intuition. What advanced analytics adds is the ability to analyze large volumes of data and infer patterns with solid statistical reasoning. This is not guesswork dressed up in numbers — it is a principled, reproducible method for detecting signals that would otherwise remain invisible until they compound into something harder to fix. The difference between a hunch and a statistically grounded finding matters, especially in regulatory settings.

There is also a more practical, meeting-room application that I have come to appreciate. Retrieval-augmented generation — systems that pair a large language model with a document corpus — can be pointed at a protocol, an amendment history, or a set of regulatory guidelines, and asked a question in plain language. In a live call with a site coordinator who needs to know how a specific edge case should be handled, the ability to surface the relevant paragraph of a 200-page protocol in seconds is not a convenience — it changes the quality and speed of the answer the site receives, and by extension, the quality of the data they generate.

Finally, there is a dimension that is easy to overlook: compliance and regulatory traceability. Everything in clinical development is documented — and increasingly, that documentation is expected to be auditable, reproducible, and traceable. A data science approach, where every transformation is logged, every decision is recorded in code, and every output can be regenerated from its inputs, fits naturally into that framework. It does not just make the work faster; it makes it more defensible.

This is the part of my background I am most actively trying to bring into my new role. Not as a way to assert that AI is the answer, but as a way to add a complementary lens to the clinical and operational expertise already at the table. The most effective trial teams I have observed combine all three — clinical judgment, operational rigor, and AI-enabled quantitative insight — and the combination is more powerful than any of them alone.

---

## Eight Months In: What I Would Tell Myself on Day One

Learn the vocabulary before you challenge the logic. Clinical development has a shared language — ICH guidelines, protocol deviations, adjudication committees, estimands — and until you speak it fluently, you will spend cognitive energy on translation that should go toward contribution.

Find the experienced trial leaders in the room who are willing to think out loud with you. The conceptual shift I described above did not happen from reading documents. It happened from conversations with people who had run outcome trials for twenty years and were generous enough to explain not just what they did, but why.

And finally: respect the slowness. The pace of clinical development is not inefficiency — it is a form of rigor that protects patients. The faster you internalize that, the less friction you will create for yourself and your team.

What I did not anticipate, eight months ago, is that the role I am still learning to do might be part of something slightly larger than a personal transition. I suspect we are beginning to see the early shape of a new kind of clinical development professional — one who does not have to choose between clinical rigor and quantitative fluency, and who can bring data science thinking to bear on trial problems without losing sight of the operational and regulatory complexity that makes those problems hard. That is not a claim about replacement. The clinical judgment and relational expertise that experienced trial leaders carry cannot be automated, and I am still building my own. It is more an observation that the field may be moving toward profiles that hold both — and that the teams who figure out how to combine them will be better positioned to run trials that are faster, cleaner, and harder to surprise.

---

*Author's Note: The views expressed here are my own and do not represent the position of Novartis or any of its affiliates. This post is part of an ongoing series reflecting on my transition from individual contributor in biomarker development to member of a clinical trial team.*

*For further details or to get in touch, visit my [personal page](https://andreagrioni.github.io/) or connect on [LinkedIn](https://www.linkedin.com/in/agrioni/).*